SELLAS Life Sciences Group, Inc. (SLS) Tops Q2 EPS by 4c

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q2 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17).

For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.

You May Also Be Interested In

• FDA accepts Teva's drug application for Tourette syndrome therapy in children
• TJX Cos. (TJX) Tops Q2 EPS by 3c, Beats on Revenue; Offers FY27 EPS Guidance
• Analog Devices climbs as fiscal Q3 results, Q4 outlook beat forecasts